In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Heat Biologics, Inc.. Trade Record

NASDAQ:HTBX Heat Biologics, Inc. stock gains 23.96% Exit Jan 24, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart HTBX Jan 4, 2019, priceSeries
About Heat Biologics, Inc.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.

Trade Information
Trade Type
Entry Date
Jan 4, 2019
Entry Price
Sell Date
Jan 24, 2019
Sell Price
Net Gain
Hold Time
13 Trading Days